Galera Announces Obsidian Merger and $350M Financing

Galera Therapeutics ( (GRTX) ) just unveiled an update.

On April 14, 2026, Galera Therapeutics and privately held Obsidian Therapeutics announced a definitive all-stock merger agreement under which both companies will become subsidiaries of a newly formed parent that will operate as Obsidian Therapeutics, Inc. and seek a Nasdaq listing under the ticker “OBX.” At closing, pre-merger Obsidian holders are expected to own about 53.2% of the combined company, pre-merger Galera shareholders about 1.8%, and investors in a concurrent private placement about 45.0%, with Galera’s stake adjustable based on its net cash.

The deal is backed by an oversubscribed $350 million concurrent private placement expected to close immediately before the merger and to fund the combined company into the second half of 2028, including through key OBX-115 data readouts in NSCLC in the first half of 2027 and melanoma by year-end 2027. Existing Galera shareholders will also receive contingent value rights tied to future proceeds from legacy assets, while support and lock-up agreements, board approvals at both companies, and customary closing conditions position the transaction to close by the third quarter of 2026, reshaping Galera as a minority holder in an immuno-oncology-focused platform centered on Obsidian’s engineered TIL pipeline.

Spark’s Take on GRTX Stock

According to Spark, TipRanks’ AI Analyst, GRTX is a Neutral.

The score is held back primarily by weak financial performance (no revenue, ongoing operating losses, and limited evidence of sustainable cash generation), despite improved balance-sheet positioning in 2025. Technicals are relatively supportive with an uptrend and positive MACD, while valuation signals are unreliable due to likely non-operating earnings. The corporate event modestly helps by improving capital-structure flexibility but carries dilution risk.

To see Spark’s full report on GRTX stock, click here.

More about Galera Therapeutics

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on advancing a pan-NOS inhibitor for patients with the hardest-to-treat forms of advanced breast cancer. The company was previously centered on developing avasopasem, a small molecule dismutase mimetic aimed at reducing chemoradiotherapy toxicities in head and neck cancer patients.

Obsidian Therapeutics, Inc., based in Cambridge, MA, is a clinical-stage biopharmaceutical company leveraging its cytoDRiVE protein-regulation platform to develop engineered tumor infiltrating lymphocyte (TIL) cell therapies for solid tumors. Its lead candidate, OBX-115, is in Phase 2 trials for advanced melanoma and Phase 1 trials for non-small cell lung cancer and has received Fast Track and RMAT designations in melanoma.

Average Trading Volume: 57,404

Technical Sentiment Signal: Hold

Current Market Cap: $3.14M

See more insights into GRTX stock on TipRanks’ Stock Analysis page.